Document is current
Any future updates will be listed below
-
Authors
Camp, Nicola J.
Madsen, Michael J.
Herranz, Jesús
Rodríguez-Lescure, Álvaro
Ruiz, Amparo
Martín, Miguel
Bernard, Philip S.
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (CA163353)
Foundation for the National Institutes of Health (CA042014)
- License Information
-
More Information
Article History
Received: 9 October 2018
Accepted: 10 December 2018
First Online: 23 January 2019
Compliance with ethical standards
:
: Philip S. Bernard is an inventor of the PAM50 gene expression signature and a stakeholder in BioClassifier LLC, a company that licensed the PAM50 know-how to Nanostring Inc for the commercialization of Prosigna.
: The study was performed in accordance with the Declaration of Helsinki, approved by the ethics committees at all participating institutions and the Spanish Health Authority, and registered at (Identifier Code: NCT00129922). Patients gave written informed consent for therapy randomization and molecular analyses.
